Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Accured Expenses (2017 - 2025)

Puma Biotechnology's Change in Accured Expenses history spans 9 years, with the latest figure at $12.9 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 193.54% year-over-year to $12.9 million; the TTM value through Dec 2025 reached $13.2 million, up 183.13%, while the annual FY2025 figure was $13.2 million, 183.13% up from the prior year.
  • Change in Accured Expenses reached $12.9 million in Q4 2025 per PBYI's latest filing, up from $5.3 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $22.2 million in Q3 2021 to a low of -$30.9 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is -$1.9 million, with a median of -$131000.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: crashed 4182.08% in 2021, then soared 1283.49% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $1.5 million in 2021, then skyrocketed by 1283.49% to $20.7 million in 2022, then plummeted by 45.26% to $11.3 million in 2023, then tumbled by 221.48% to -$13.8 million in 2024, then surged by 193.54% to $12.9 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Change in Accured Expenses are $12.9 million (Q4 2025), $5.3 million (Q3 2025), and $4.9 million (Q2 2025).